Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study
Carregando...
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
UEMA, Deise
SIEPMANN, Timo
ANGEL, Martin
REGO, Juliana F. M.
WESCHENFELDER, Rui
ROCHA FILHO, Duilio R.
COSTA, Frederico P.
Citação
JOURNAL OF CLINICAL MEDICINE, v.8, n.3, article ID 405, 11p, 2019
Resumo
The background to this study was that factors associated with carcinoid heart disease (CHD) and its impacts on overall survival (OS) are scantly investigated in patients (pts) with neuroendocrine tumors (NETs). In terms of materials and methods, a retrospective multicenter cohort study was conducted of factors associated with CHD in advanced NET pts with carcinoid syndrome (CS) and/or elevated urinary 5-hidroxyindole acetic acid (u5HIAA). CHD was defined as at least moderate right valve alterations. The results were the following: Among the 139 subjects included, the majority had a midgut NET (54.2%), 81.3% had CS, and 93% received somatostatin analogues. In a median follow-up of 39 months, 48 (34.5%) pts developed CHD, with a higher frequency in pts treated in public (77.2%) versus private settings (22.9%). In a multivariate logistic regression, unknown primary or colorectal NETs (Odds Ratio (OR) 4.35; p = 0.002), at least 50% liver involvement (OR 3.45; p = 0.005), and being treated in public settings (OR 4.76; p = 0.001) were associated with CHD. In a Cox multivariate regression, bone metastases (Hazard Ratio {HR} 2.8; p = 0.031), CHD (HR 2.63; p = 0.038), and a resection of the primary tumor (HR 0.33; p = 0.026) influenced the risk of death. The conclusions were the following: The incidence of CHD was higher in pts with a high hepatic tumor burden and in those treated in a public system. Delayed diagnosis and limited access to effective therapies negatively affected the lives of NET patients.
Palavras-chave
neuroendocrine tumors, carcinoid heart disease, carcinoid syndrome, somatostatin analogues, metastases
Referências
- Alves C, 2018, ECANCERMEDICALSCIENC, V12, DOI 10.3332/ecancer.2018.879
- Connolly HM, 2015, J AM COLL CARDIOL, V66, P2189, DOI 10.1016/j.jacc.2015.09.014
- Connolly HM, 2001, CIRCULATION, V104, pI36
- Dobson R, 2014, BRIT J CANCER, V111, P1703, DOI 10.1038/bjc.2014.468
- Dobson R, 2014, INT J CARDIOL, V173, P29, DOI 10.1016/j.ijcard.2014.02.037
- FELDMAN JM, 1982, ANN SURG, V196, P33, DOI 10.1097/00000658-198207000-00008
- Fox DJ, 2004, HEART, V90, P1224, DOI 10.1136/hrt.2004.040329
- Grozinsky-Glasberg S, 2015, NEUROENDOCRINOLOGY, V101, P263, DOI 10.1159/000381930
- Gustafsson BI, 2008, INT J CARDIOL, V129, P318, DOI 10.1016/j.ijcard.2008.02.019
- HAQ AU, 1992, MED PEDIATR ONCOL, V20, P221, DOI 10.1002/mpo.2950200307
- Moller JE, 2003, NEW ENGL J MED, V348, P1005, DOI 10.1056/NEJMoa021451
- Mota JM, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.662
- Pape UF, 2012, NEUROENDOCRINOLOGY, V95, P135, DOI 10.1159/000335629
- PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188
- Raja SG, 2010, FUTUR CARDIOL, V6, P647, DOI 10.2217/FCA.10.87
- Riechelmann RP, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.716
- Ferrari ACRD, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e490s
- STROBE, 2007, PLOS MED
- Warner RRP, 2015, J AM COLL CARDIOL, V66, P2197, DOI 10.1016/j.jacc.2015.05.086
- Westberg G, 2001, BRIT J SURG, V88, P865, DOI 10.1046/j.0007-1323.2001.01798.x
- Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377